Floatz logo

Nicotine

Cerebrovascular Disorders

Ottawa Heart Institute Research CorporationSmall moleculePhase 4 / ApprovedDormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Cerebrovascular Disorders cohort.

Asset / SponsorPhaseRating
Wellbutrin
Ottawa Heart Institute Research Corporation
Phase 4BB
Acetylsalicylic Acid
The Second Hospital of Anhui Medical University
Phase 3BB
Varenicline Tartrate
Ottawa Heart Institute Research Corporation
Phase 4BB
Tenecteplase
University of Melbourne
Phase 3BB
Xeomin®
Sisli Hamidiye Etfal Training and Research Hospital
Phase 4BB

View all 19 →

Same molecule, other indications

Nicotine is also rated in:

nicotine dependenceDormant
A
Indicative ·
83 / 100
View asset →
nicotine dependenceDormant
BBB
Indicative ·
73 / 100
View asset →
cognitive disorderDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →